Last reviewed · How we verify
HemaMax
At a glance
| Generic name | HemaMax |
|---|---|
| Also known as | rHuIL-12, NM-IL-12 |
| Sponsor | Neumedicines Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) (PHASE2)
- NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds (PHASE2)
- Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome (PHASE2)
- Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HemaMax CI brief — competitive landscape report
- HemaMax updates RSS · CI watch RSS
- Neumedicines Inc. portfolio CI